Regeneron (REGN) director Arthur Ryan sells 200 shares in pre-planned trade
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
REGENERON PHARMACEUTICALS, INC. director Arthur F. Ryan reported an open-market sale of 200 shares of common stock on July 2, 2026 at a volume-weighted average price of $650.15 per share. The trade was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on October 31, 2025, indicating it was scheduled in advance. Following this transaction, Ryan directly holds 17,303 shares of Regeneron common stock.
Positive
- None.
Negative
- None.
Insights
Small, pre-planned director sale that appears routine in size.
Director Arthur F. Ryan sold 200 shares of Regeneron common stock at a volume-weighted average of about $650.15 per share. The transaction is coded as an open-market sale and leaves him with 17,303 directly held shares.
The filing states the sale was made under a Rule 10b5-1(c) trading plan adopted on October 31, 2025. Such plans pre-schedule trades, reducing the informational value of the exact timing. Relative to his remaining holdings, the sale is small and looks like routine portfolio management rather than a major change in exposure.
Insider Trade Summary 10b5-1
Net Seller: 200 shares ($130,030)
Net Sell
1 txn
Insider
RYAN ARTHUR F
Role
null
Sold
200 shs ($130K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 200 | $650.15 | $130K |
Holdings After Transaction:
Common Stock — 17,303 shares (Direct, null)
Footnotes (1)
- Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.
Key Figures
Shares sold: 200 shares
Average sale price: $650.15 per share
Post-transaction holdings: 17,303 shares
+2 more
5 metrics
Shares sold
200 shares
Open-market sale on July 2, 2026
Average sale price
$650.15 per share
Volume-weighted average sale price
Post-transaction holdings
17,303 shares
Shares directly held after the sale
Price range
$650.10–$650.19 per share
Range of individual trade prices on July 2, 2026
Trading plan adoption date
October 31, 2025
Rule 10b5-1(c) plan governing this sale
Key Terms
Rule 10b5-1(c), volume-weighted average price, open-market sale, Form 4
4 terms
Rule 10b5-1(c) regulatory
"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
volume-weighted average price financial
"Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19."
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did Regeneron (REGN) director Arthur F. Ryan report?
Arthur F. Ryan reported selling 200 shares of Regeneron common stock. The sale occurred on July 2, 2026 as an open-market transaction, with a volume-weighted average price of about $650.15 per share, according to the Form 4 filing data.
What does the volume-weighted average price disclosure mean in this Regeneron (REGN) Form 4?
The Form 4 reports a volume-weighted average sale price of $650.15 for the 200 shares. It explains that individual trades ranged from $650.10 to $650.19 and notes full pricing details are available upon request.